On Wednesday, Leerink Partners maintained its Market Perform rating on shares of Theravance Biopharma (NASDAQ:TBPH) with a steady price target of $10.00. The biopharmaceutical company reported third-quarter 2024 results that surpassed expectations in terms of total revenue and operating income but fell short on earnings per share due to a non-cash impairment charge.
Theravance Biopharma's total revenue for the quarter was 12% higher than consensus estimates, and operating income was 13% above. This performance was despite earnings per share being 5% lower, largely attributed to the non-cash impairment. The company's Yupelri sales outperformed, coming in 12% above consensus, which was fueled by a 14% increase in volume. However, this was offset by a 7% negative impact from pricing.
The company has taken steps to address the negative channel mix shift by establishing a Yupelri-dedicated hub. The effectiveness of this initiative is anticipated to be reported in future updates.
Moreover, Yupelri is set to receive a 10% price increase in July 2024, with the full impact expected to reflect in Medicare Average Selling Prices (ASPs) in January 2025, and a 2% price increase in October 2024, to be fully reflected in April 2025's Medicare ASPs.
Furthermore, Theravance Biopharma announced organizational changes, including the formation of a Strategic Review Committee and the separation of the roles of CEO and Chair of the Board. Susannah Grey, formerly the CFO of Royalty Pharma (not rated), has been appointed as the new Chair of the Board. The firm reiterated its Market Perform rating on the stock, indicating a neutral stance on Theravance Biopharma's shares.
In other recent news, Theravance Biopharma has reported a positive third quarter for 2024. The company's earnings show a significant increase in the sales of its respiratory drug, YUPELRI, which reached $62.2 million, marking a 7% increase year-over-year. Hospital demand for YUPELRI has also surged by 14%, with a 40% increase in doses compared to the same quarter last year.
In other developments, the company's collaboration revenue rose to $16.9 million, an 8% year-over-year increase. Theravance Biopharma is also making progress in its clinical studies, notably the CYPRESS study for Ampreloxetine, which is expected to be completed by mid-2025.
The company has made strategic changes including the separation of CEO and Chair roles, with Susannah Gray appointed as Chair. Moreover, a committee has been established to review strategic alternatives for key assets. The company has also expressed its intention to return excess capital to shareholders. These are recent developments that contribute to the company's ongoing growth and strategic progress.
InvestingPro Insights
Recent InvestingPro data provides additional context to Theravance Biopharma's (NASDAQ:TBPH) financial performance and market position. The company's market capitalization stands at $498.03 million, with a revenue of $62.02 million for the last twelve months as of Q2 2024. Notably, TBPH has demonstrated strong revenue growth of 20.97% over the same period, aligning with the positive sales performance mentioned in the article.
InvestingPro Tips highlight that management has been aggressively buying back shares, which could be seen as a vote of confidence in the company's future prospects. Additionally, TBPH holds more cash than debt on its balance sheet, potentially providing financial flexibility as it navigates market challenges and pursues growth initiatives like the Yupelri-dedicated hub mentioned in the article.
It's worth noting that while the company's recent quarterly results were mixed, with revenue outperforming but earnings falling short, InvestingPro data shows that TBPH's stock has seen a 7.22% price total return over the past month. This suggests that investors may be focusing on the company's revenue growth and potential future improvements in pricing and market positioning for Yupelri.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Theravance Biopharma, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.